Related Experiment Video

Updated: May 9, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

[Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary

Ibrahim Halil Tanboğa1, Mehmet Mustafa Can, Alper Ozkan

  • 1Department of Cardiology, Atatürk University Faculty of Medicine, Erzurum, Turkey. haliltanboga@yahoo.com

Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|August 7, 2013
PubMed

Insights

Human Platelet Antigen-1 (HPA-1) gene polymorphism is not linked to coronary artery disease (CAD) risk or altered platelet function in patients undergoing percutaneous coronary intervention. This study found no association between HPA-1 variants and clopidogrel resistance.

Area of Science:

  • Cardiovascular Genetics
  • Platelet Biology
  • Pharmacogenomics

Background:

  • Human Platelet Antigen-1 (HPA-1) gene polymorphism has been investigated for its potential association with coronary artery disease (CAD) and its impact on platelet function.
  • Understanding this relationship is crucial for personalized medicine approaches in cardiovascular care.

Purpose of the Study:

  • To investigate the distribution of HPA-1 gene polymorphism in patients with angiographic CAD compared to a control group.
  • To determine the association between HPA-1 gene polymorphism and platelet aggregation, including clopidogrel resistance, in CAD patients.

Main Methods:

  • A case-control study involving 94 patients with angiographic CAD and 115 controls.
  • Platelet aggregation assessed using impedance aggregometry post-percutaneous coronary intervention (PCI).
  • HPA-1 gene polymorphism analyzed from blood samples at discharge.

Main Results:

  • No significant difference in HPA-1 allele distribution (A vs. B) was observed between the CAD and control groups.
  • HPA-1 gene polymorphism did not correlate with clopidogrel resistance, defined as platelet aggregation >480 AU*min.
  • In the CAD group, platelet aggregation levels did not significantly differ between HPA-1A and HPA-1B alleles.

Conclusions:

  • The HPA-1 gene polymorphism distribution is similar in CAD patients and the general population.
  • HPA-1 gene polymorphism is not associated with altered platelet aggregation or clopidogrel resistance in patients with CAD.
Abstract

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...